The researchers, among them Jose Luis Fernandez Moon (Molecular Genetics Unit) and Victor Taboada Mtnez (S. Rheumatology) analyzed in paper ASCC1 (activating signal cointegrator 1 complex subunit 1) a potent inhibitor of NFkB activation and They conclude that an inactive variant ASCC1 contributes to prognosis of patients with rheumatoid arthritis.
The study of the known key implication of NFKB in the phenomena of inflammation that are the central phenomenon of Rheumatoid Arthritis. In the first phase of the study analyzed 158 regulators NFkB pathway in patients with rheumatoid arthritis using techniques Next-generation sequencing in patients with rheumatoid arthritis and healthy controls, and this analysis ASCC1 selected for study.
Having established the role of the inactive variant ASCC1, analysis of more than 400 patients with rheumatoid arthritis for the first time to detect an association between the inactive variant and severity of rheumatoid arthritis. The study is being replicated in a larger cohort.
The article was published in the prestigious Journal of Immunology and cited and summarized in Nature Review Rheumatology.
Reference: S Torices, Alvarez-Rodriguez L, Big L, R Varela, Munoz P, Pascual D raft, Lopez-Hoyos M, V Martinez-Taboada, Fernandez JL-Moon. The Truncated Variant of ASCC1 the Novel Inhibitor of NF-kB, Is Associated With Disease Severity in Patients with Rheumatoid Arthritis. J Immunol. 2015 Oct 26. IIP 1501532. [Epub ahead of print]